BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12738346)

  • 1. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
    Jaffe JH; O'Keeffe C
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
    Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.
    Bonhomme J; Shim RS; Gooden R; Tyus D; Rust G
    J Natl Med Assoc; 2012; 104(7-8):342-50. PubMed ID: 23092049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
    Jordan CJ; Cao J; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
    Johnson RE; Chutuape MA; Strain EC; Walsh SL; Stitzer ML; Bigelow GE
    N Engl J Med; 2000 Nov; 343(18):1290-7. PubMed ID: 11058673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing surveillance of methadone and buprenorphine in the United States.
    Dasgupta N; Bailey EJ; Cicero T; Inciardi J; Parrino M; Rosenblum A; Dart RC
    Pain Med; 2010 Jul; 11(7):1078-91. PubMed ID: 20545875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting.
    Clark HW
    Postgrad Med; 2001 Jun; 109(6):15-6, 25. PubMed ID: 11424343
    [No Abstract]   [Full Text] [Related]  

  • 11. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
    Wiegand TJ
    J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine and addiction: challenges for the pharmacist.
    Boatwright DE
    J Am Pharm Assoc (Wash); 2002; 42(3):432-8. PubMed ID: 12030630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine.
    Ling W; Rawson RA; Compton MA
    J Psychoactive Drugs; 1994; 26(2):119-28. PubMed ID: 7931856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine: reflections of an addictions psychiatrist.
    Selzer J
    J Clin Psychiatry; 2006 Sep; 67(9):1466-7. PubMed ID: 17017836
    [No Abstract]   [Full Text] [Related]  

  • 18. Treating opioid dependence. Growing implications for primary care.
    Krantz MJ; Mehler PS
    Arch Intern Med; 2004 Feb; 164(3):277-88. PubMed ID: 14769623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analgesic management of acute pain in patients receiving methadone or buprenorphine].
    Zinck L; Sonne NM; Madsen SL; Nikolajsen L
    Ugeskr Laeger; 2015 Mar; 177(10):. PubMed ID: 25749118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain.
    Wachholtz A; Gonzalez G
    Drug Alcohol Depend; 2014 Dec; 145():143-9. PubMed ID: 25456326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.